SVRA vs. AVTE, PRAX, PHAR, IRON, COGT, YMAB, SIGA, SLN, WVE, and LYEL
Should you be buying Savara stock or one of its competitors? The main competitors of Savara include Aerovate Therapeutics (AVTE), Praxis Precision Medicines (PRAX), Pharming Group (PHAR), Disc Medicine (IRON), Cogent Biosciences (COGT), Y-mAbs Therapeutics (YMAB), SIGA Technologies (SIGA), Silence Therapeutics (SLN), Wave Life Sciences (WVE), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical preparations" industry.
Aerovate Therapeutics (NASDAQ:AVTE) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation.
Aerovate Therapeutics currently has a consensus price target of $49.33, suggesting a potential upside of 128.71%. Savara has a consensus price target of $8.20, suggesting a potential upside of 84.27%. Given Savara's higher possible upside, equities research analysts clearly believe Aerovate Therapeutics is more favorable than Savara.
Savara is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aerovate Therapeutics' return on equity of -46.27% beat Savara's return on equity.
Aerovate Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Savara received 268 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 65.74% of users gave Savara an outperform vote while only 64.00% of users gave Aerovate Therapeutics an outperform vote.
87.9% of Savara shares are owned by institutional investors. 19.3% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 4.6% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Aerovate Therapeutics had 3 more articles in the media than Savara. MarketBeat recorded 8 mentions for Aerovate Therapeutics and 5 mentions for Savara. Aerovate Therapeutics' average media sentiment score of 0.49 beat Savara's score of 0.36 indicating that Savara is being referred to more favorably in the news media.
Summary
Savara beats Aerovate Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Savara News Delivered to You Automatically
Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
